Today: 29 April 2026
Browse Category

OTC:FNMA 12 November 2025 - 9 January 2026

FNMA stock in focus after Trump’s $200bn mortgage bond order and fresh IPO talk

FNMA stock in focus after Trump’s $200bn mortgage bond order and fresh IPO talk

Fannie Mae shares rose 1.5% to $10.85 on Jan. 8 after President Trump said he ordered $200 billion in mortgage bond purchases to lower rates. FHFA chief Bill Pulte said Trump may decide within two months on a possible Fannie-Freddie IPO. Freddie Mac reported the average 30-year mortgage rate at 6.16%. Fannie Mae also released a 2026 plan for $4 billion in credit-risk transfer deals.
9 January 2026
··
Fannie Mae (FNMA) Stock Surges on Michael Burry Bet and IPO Hopes: Latest News, Forecasts and Risks as of December 10, 2025

Fannie Mae (FNMA) Stock Surges on Michael Burry Bet and IPO Hopes: Latest News, Forecasts and Risks as of December 10, 2025

Fannie Mae shares rose 4.5% to $11.95 on December 9 and are up 21% in two weeks, driven by Michael Burry’s disclosure of a large stake and renewed speculation about a public relisting. Trading volumes reached several million shares daily. Burry’s thesis and Trump-era spin-off talk have fueled investor interest despite ongoing regulatory hurdles.
10 December 2025
···
Federal National Mortgage Association (Fannie Mae) Stock in December 2025: Michael Burry’s Big Bet, Trump’s IPO Plans and What Comes Next

Federal National Mortgage Association (Fannie Mae) Stock in December 2025: Michael Burry’s Big Bet, Trump’s IPO Plans and What Comes Next

Fannie Mae’s stock closed at $11.44 on December 8, up 8% over five days and nearly 250% year-to-date, according to MarketScreener. Shares jumped after investor Michael Burry disclosed sizable stakes in both Fannie Mae and Freddie Mac and predicted IPOs for the mortgage giants. Fannie’s 52-week range spans $2.24 to $15.98, highlighting recent volatility.
9 December 2025
····
Fannie Mae (FNMA) News Today — Nov. 12, 2025: Servicing Guide Update, DU Credit-Score Shift, and 50‑Year Mortgage Debate

Fannie Mae (FNMA) News Today — Nov. 12, 2025: Servicing Guide Update, DU Credit-Score Shift, and 50‑Year Mortgage Debate

Fannie Mae will remove the 620 minimum credit score for Desktop Underwriter® on new loan casefiles starting Nov. 16, 2025. A Servicing Guide update adds a new bankruptcy attorney fee effective Dec. 1 and clarifies cramdown rules for recourse loans. Refinance volume fell 15.9% last week but remains up year over year. The White House is considering 50-year mortgages; FHFA weighs “portable” mortgages.
12 November 2025
·

Stock Market Today

  • Nasdaq Futures Rise Ahead of Fed Decision and Major Tech Earnings
    April 29, 2026, 9:10 AM EDT. Nasdaq futures gained 0.4% ahead of the Federal Reserve's policy decision and earnings reports from tech giants Alphabet, Microsoft, Amazon, and Meta. Markets are cautious following a broad sell-off in major indices driven by chip stock weakness linked to slowing growth at AI firm OpenAI. Investors await the Fed's stance on inflation and interest rates, with crude oil prices rising amid unresolved US-Iran tensions. The Fed is expected to hold rates steady in Jerome Powell's final meeting before his replacement, Kevin Warsh, awaits Senate approval. Key focus remains on AI capital expenditure and the potential for further rate hikes in 2024. Earnings from AbbVie, AstraZeneca, Total Energies, UBS, and GSK are also in focus.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop